GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Guilin Sanjin Pharmaceutical Co 002275.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

17.15

-5.77%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥2.05bn

FY2016FY2025

Net income

CN¥433.1m

FY2016FY2025

Free cash flow

CN¥621.2m

FY2016FY2025

Shareholders' equity

CN¥3.19bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥2.05bnCN¥2.19bnCN¥2.17bnCN¥1.96bnCN¥1.74bnCN¥1.57bnCN¥1.64bnCN¥1.58bnCN¥1.62bnCN¥1.53bn
Gross profitCN¥1.56bnCN¥1.58bnCN¥1.57bnCN¥1.39bnCN¥1.28bnCN¥1.12bnCN¥1.20bnCN¥1.15bnCN¥1.23bnCN¥1.12bn
Research and developmentCN¥160.0mCN¥173.3mCN¥158.1mCN¥217.0mCN¥202.4mCN¥154.3mCN¥104.1mCN¥64.7mCN¥58.2mCN¥65.6m
Operating incomeCN¥568.1mCN¥644.8mCN¥518.3mCN¥446.8mCN¥429.0mCN¥354.7mCN¥469.4mCN¥498.3mCN¥564.7mCN¥467.4m
Net incomeCN¥433.1mCN¥521.5mCN¥421.3mCN¥329.5mCN¥343.7mCN¥277.0mCN¥392.1mCN¥413.3mCN¥464.4mCN¥393.7m
Diluted earnings per share0.740.890.720.560.600.521.050.700.790.67

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥4.26bnCN¥4.23bnCN¥3.94bnCN¥3.96bnCN¥4.10bnCN¥3.88bnCN¥3.42bnCN¥3.41bnCN¥3.23bnCN¥2.87bn
Cash and short-term investments—CN¥1.68bnCN¥1.36bnCN¥1.43bnCN¥1.70bnCN¥1.72bnCN¥1.24bnCN¥1.22bnCN¥733.5mCN¥719.8m
Total liabilitiesCN¥1.07bnCN¥1.22bnCN¥1.12bnCN¥1.15bnCN¥1.26bnCN¥923.3mCN¥600.2mCN¥599.5mCN¥575.7mCN¥444.3m
DebtCN¥180.9mCN¥475.6mCN¥409.1mCN¥465.9mCN¥609.1mCN¥399.5mCN¥184.2mCN¥100.0mCN¥100.0mCN¥50.0m
Shareholders' equityCN¥3.19bnCN¥3.01bnCN¥2.82bnCN¥2.81bnCN¥2.84bnCN¥2.96bnCN¥2.82bnCN¥2.81bnCN¥2.65bnCN¥2.43bn
Shares outstanding588m584m582m584m569m531m374m590m590m590m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥708.1mCN¥588.3mCN¥549.2mCN¥528.7mCN¥410.2mCN¥598.0mCN¥468.3mCN¥551.7mCN¥387.8mCN¥536.9m
Capital spending−CN¥86.9m−CN¥82.2m−CN¥76.4m−CN¥62.3m−CN¥144.1m−CN¥205.5m−CN¥226.1m−CN¥90.0m−CN¥61.5m−CN¥65.4m
Free cash flowCN¥621.2mCN¥506.2mCN¥472.9mCN¥466.4mCN¥266.2mCN¥392.5mCN¥242.1mCN¥461.8mCN¥326.3mCN¥471.5m
Dividends paid−CN¥341.0m−CN¥336.1m−CN¥427.8m−CN¥528.8m−CN¥460.2m−CN¥132.3m−CN¥203.9m−CN¥238.9m−CN¥240.6m−CN¥296.6m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥443.5mCN¥525.1mCN¥583.3mCN¥464.0mCN¥531.8mCN¥466.6mCN¥619.2mCN¥506.4m
Gross profitCN¥310.8mCN¥432.0mCN¥455.2mCN¥343.9mCN¥393.3mCN¥362.8mCN¥404.9mCN¥380.2m
Operating incomeCN¥171.8mCN¥192.4mCN¥106.8mCN¥113.8mCN¥212.5mCN¥130.0mCN¥179.8mCN¥109.7m
Net incomeCN¥136.3mCN¥124.4mCN¥47.9mCN¥98.4mCN¥182.0mCN¥104.8mCN¥137.7mCN¥82.9m
Diluted earnings per share0.230.210.080.170.310.180.240.14
Cash from operations———CN¥117.0mCN¥270.0mCN¥45.0m—CN¥48.0m
Capital spending−CN¥20.0m−CN¥13.0m—−CN¥124.0m−CN¥21.0m−CN¥17.0m−CN¥44.0m−CN¥35.0m
Free cash flow———−CN¥7.0mCN¥249.0mCN¥28.0m—CN¥13.0m
Total assetsCN¥4.04bnCN¥4.32bnCN¥4.26bnCN¥4.30bnCN¥4.23bnCN¥4.33bnCN¥4.23bnCN¥3.93bn
Cash and short-term investments———CN¥1.71bnCN¥1.66bnCN¥1.97bnCN¥1.68bnCN¥1.42bn
DebtCN¥226.6mCN¥244.6mCN¥180.9mCN¥463.2mCN¥516.5mCN¥519.1mCN¥446.8mCN¥433.4m
Shareholders' equityCN¥3.26bnCN¥3.32bnCN¥3.19bnCN¥3.24bnCN¥3.13bnCN¥3.13bnCN¥3.01bnCN¥3.01bn

Financial ratios

Data as of 8 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin76.0%72.2%72.3%70.7%73.8%71.3%
Operating margin27.2%21.9%21.2%16.1%18.7%20.0%
Net margin21.2%23.8%19.4%16.8%19.7%17.7%
Return on equity13.6%17.3%15.0%11.7%12.1%9.4%
Return on assets10.2%12.3%10.7%8.3%8.4%7.1%
Free cash flow yield11.1%9.4%8.8%8.3%8.0%12.4%
Revenue growth-6.8%1.0%10.8%12.5%11.2%-4.5%
Earnings growth-16.9%23.8%27.8%-4.1%24.1%-29.4%
Current ratio3.01x2.58x2.46x2.71x2.96x4.04x
Debt to equity0.06x0.15x0.12x0.10x0.17x0.14x
Equity ratio74.9%71.1%71.6%71.0%69.3%76.2%
Interest coverage28.04x34.10x27.57x15.34x17.19x27.12x
R&D as a share of sales7.8%7.9%7.3%11.1%11.6%9.8%
Buybacks as a share of market value-0.6%-0.4%0.4%-2.8%-7.0%-42.1%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue1.4%5.5%3.9%
Operating income8.3%9.9%3.0%
Net income9.5%9.4%1.4%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin74.0%72.8%72.7%73.0%
Operating margin28.6%26.0%25.4%27.7%
Net margin22.5%20.4%19.9%22.5%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings19.116.920.023.428.028.612.518.320.627.6
Price to sales4.04.03.93.95.55.13.04.85.97.1

Dividends and splits

Per share, in the currency the company pays

Paid for 16 years. Last went ex-dividend on 4 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.300.550.550.700.900.800.230.35
  • 13-for-10 split · 21 Apr 2011

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.